# Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects

> **NCT00529763** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 121 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00529763
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-17
- **Primary completion:** 2009-06-17
- **Final completion:** 2022-04-20
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2023-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529763, "Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00529763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*